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Plasmodium  parasites  are the causative  agent  of human  malaria,  and  the  development  of a highly  effec-
tive  vaccine  against  infection,  disease  and  transmission  remains  a  key priority.  It is widely  established
that  multiple  stages  of the  parasite’s  complex  lifecycle  within  the  human  host  and mosquito  vector  are
susceptible  to vaccine-induced  antibodies.  The  mainstay  approach  to  antibody  induction  by  subunit  vac-
cination  has  been  the  delivery  of  protein  antigen  formulated  in adjuvant.  Extensive  efforts  have been
made  in  this  endeavor  with  respect  to malaria  vaccine  development,  especially  with  regard  to  target
antigen  discovery,  protein  expression  platforms,  adjuvant  testing,  and  development  of soluble  and  virus-
like particle  (VLP)  delivery  platforms.  The  breadth  of  approaches  to protein-based  vaccines  is  continuing
to  expand  as  innovative  new  concepts  in next-generation  subunit  design  are  explored,  with  the  prospects
for  the  development  of  a highly  effective  multi-component/multi-stage/multi-antigen  formulation  seem-
ing ever  more  likely.  This review  will  focus  on  recent  progress  in  protein  vaccine  design,  development
and/or  clinical  testing  for a number  of leading  malaria  antigens  from  the  sporozoite-,  merozoite-  and
sexual-stages  of  the  parasite’s  lifecycle–including  PfCelTOS,  PfMSP1,  PfAMA1,  PfRH5,  PfSERA5,  PfGLURP,
PfMSP3,  Pfs48/45  and  Pfs25.  Future  prospects  and  challenges  for the development,  production,  human
delivery  and  assessment  of  protein-based  malaria  vaccines  are  discussed.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Multiple stages of the Plasmodium parasite’s lifecycle are sus-
eptible to antibodies, including the liver-invasive sporozoite; the
ed blood cell (RBC)-invading merozoite; parasite stages within
he infected erythrocyte (iRBC) which display antigen at the cell
urface; as well as the sexual-stage forms present in both the
uman host and mosquito vector. This susceptibility has led to
yriad efforts to develop subunit vaccines that can induce func-ional antibodies capable of preventing malaria infection, disease
r transmission [1].
∗ Corresponding author. Tel.: +44 1865 617624; fax: +44 1865 617608.
E-mail address: simon.draper@ndm.ox.ac.uk (S.J. Draper).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.093
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uAll subunit vaccines in their most basic form require deliv-
ery of antigen(s) believed to be targets of protective immunity,
coupled with an immuno-stimulant or ‘adjuvant’ selected in the
belief that this will lead to the induction of a strong and durable
immune response of the appropriate type. Even these most basic
of tenets have proved challenging in the context of antibody-
inducing subunit vaccines for malaria, but much progress has been
made.
The classical approach to antibody induction by subunit vac-
cination has been the delivery of protein antigen formulated in
adjuvant, with notable success in humans including examples
such as hepatitis B virus surface antigen (HBsAg) and bacterial
toxoids (tetanus and diphtheria). In the case of malaria, the produc-
tion of conformational recombinant proteins using heterologous
expression platforms can prove challenging, especially when using
bacterial-based systems [2]. However, numerous protein vaccine
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Progress in the clinical development and testing of malaria vaccine candidates comprising recombinant protein/peptide/VLP and adjuvant.
References
Recombinant malaria antigens progressed to clinical testing
PfCSP; PfTRAP; PfCelTOS; PfAMA1; PfLSA1; PfLSA3; PfMSP1; PfMSP2; PfMSP3; PfGLURP; PfRESA; Pf27A;
Pf11.1; PfEBA175; PfSERA5; Pfs230; Pfs25; PvCSP; Pvs25; [PfRH5; VAR2CSA; Pfs48/45; PvDBP].
[173–178] Clinicaltrials.gov NCT00312702;
NCT00509158; NCT01949909; NCT01605786
Heterologous expression systems used for cGMP manufacture
E.  coli; S. cerevisiae; P. pastoris; L. lactis; N. benthamiana; Pseudomonas ﬂuorescens; Drosophila S2 cells. [179]
Recombinant antigen delivery platforms tested in clinical trials
Soluble protein; LSP; fusion protein; HBsAg VLP; EPA conjugate; Alfalfa mosaic virus coat protein VLP;
virosome.
[180]
Protein adjuvants tested in clinical trials
Adjuphos (aluminum phosphate); Alhydrogel (aluminum hydroxide/alum); Alhydrogel + CPG7909; AS01B;
AS02A; Montanide ISA720; Montanide ISA51; GLA-SE.
[61,176]
A isted. 
c ded w
R tigen
c
M
E
p
s
a
e
r
s
h
t
n
c
t
m
p
s
W
g
p
a
p
d
c
w
a
y
o
t
a
a
b
c
c
p
v
c
D
f
s
c
l
s
v
[
m
(ntigens, heterologous expression platforms, delivery platforms and adjuvants are l
linical  testing are shown in square parentheses. Exemplar references are only inclu
ESA  = ring-infected erythrocyte surface antigen; EBA-175 = erythrocyte-binding an
andidates have now been successfully produced to current Good
anufacturing Practice (cGMP) standard (using amongst others
scherichia coli, Saccharomyces cerevisiae and Pichia pastoris), and
rogressed to Phase I/II clinical testing (Table 1). Clinical progres-
ion also requires access to adjuvants which are safe and display
cceptable reactogenicity proﬁles [3], but in turn are capable of
liciting antibody responses of sufﬁcient magnitude to prevent
apidly invading or developing parasites. Our incomplete under-
tanding of protective immune effector mechanisms in vivo in
umans also continues to hamper vaccine development and priori-
ization [4]. Whether antibodies function through cell-independent
eutralization type mechanisms or via Fc-mediated immune
ell interactions is often unclear, as is the potential contribu-
ion of CD4+ T helper cell responses to B cell induction and
emory maintenance, and IgG afﬁnity maturation and subtype
olarization. How adjuvant selection and antigen delivery can
kew these parameters in humans is still poorly understood.
ith regard to antigen target selection, the malaria parasite
enome possesses over 5000 genes, with complex expression
atterns throughout all stages of the lifecycle [5]. The historical
bsence of biological information on the vast majority of gene
roducts has meant that subunit vaccine development has tra-
itionally focused on a relatively limited number of well-studied
andidates.
Despite these great challenges, huge progress has been made
ith recombinant protein malaria subunits. Numerous antigens
nd adjuvants have now been tested in Phase I/II clinical trials
ielding important and informative clinical data (Table 1). A variety
f expression platforms have been used to produce soluble pro-
eins, fusion antigens, long synthetic peptides (LSP), conjugates and
ntigen arrayed on virus-like particles (VLPs). Indeed, the leading
nti-sporozoite subunit vaccine, RTS,S/AS01B, based on a recom-
inant VLP of HBsAg displaying repeats from the P. falciparum
ircumsporozoite protein (PfCSP), has shown moderate level efﬁ-
acy of modest duration in Phase II/III clinical trials [6–8] and is
rogressing toward licensure. The breadth of approaches to protein
accine design is now continuing to expand as innovative new con-
epts in next-generation subunit design and antigen discovery [see
oolan et al. in this review series] are explored, with the prospects
or the development of a highly effective multi-component/multi-
tage/multi-antigen formulation seeming ever more likely.
This review will focus on recent progress in protein vac-
ine design, development and/or clinical testing for a number of
eading malaria antigens from the sporozoite-, merozoite- and
exual-stages of the parasite’s lifecycle. Progress with PfCSP-based
accines, especially RTS,S, has been reviewed in detail elsewhere
9,10] and in this Special Issue [Kaslow et al.], and the develop-
ent of protein vaccines against the P. vivax Duffy-binding protein
PvDBP) are also covered in another article in this review seriesProtein-based antigens reported to be in clinical development but not yet in Phase I
hen information is not provided elsewhere in this review. LSA = liver-stage antigen;
-175 kDa.
[Chitnis et al.]. Future prospects and challenges for this ﬁeld will be
summarized.
2. Antigen candidates
2.1. PfCelTOS
Signiﬁcant efforts are currently focused on identifying promis-
ing antigenic targets expressed on sporozoites and in early
liver-stage development with the intent to combine and syner-
gize immune responses against these two stages of the lifecycle.
The P. falciparum cell traversal protein of ookinetes and sporo-
zoites (PfCelTOS), independently identiﬁed by mining genomic [11]
and expression [12] sequence databases, is a micronemal secreted-
protein. This antigen has been implicated in host cell-traversal and
invasion during both motile life-stages of the parasite, thus sup-
porting its candidacy as a pre-erythrocytic target.
Initial studies in mice demonstrated protective efﬁcacy against
a heterologous P. berghei challenge using a codon-harmonized,
E. coli-expressed PfCelTOS [13]. These antibodies recognized both
P. falciparum and P. berghei sporozoites, and inhibited gliding motil-
ity and hepatocyte invasion in vitro. Recently, the contribution of
antibodies and T cells as the effectors against parasites at the site
of infection was  veriﬁed using In vivo Imaging System (IVIS) [14].
In studies using an experimental clinical-grade adjuvant – a syn-
thetic TLR4 agonist in a stable oil-in-water emulsion designed to
enhance humoral and cell-mediated immunity (GLA-SE) – Th1-
biased immune responses (with higher IgG2a antibodies, IFN-
responses and long-lived antibody-secreting cells) were observed
in BALB/c mice as compared to mice immunized with the same anti-
gen in Montanide ISA720 [15]. However, when this formulation was
tested in a ﬁrst-in-human clinical trial, while safe and immuno-
genic, no protective efﬁcacy was  observed against controlled
human malaria infection (CHMI) (J. Cowden, personal communi-
cation). A subsequent Phase Ia trial with PfCelTOS in GSK’s AS01B
adjuvant is currently ongoing (Clinicaltrials.gov NCT02174978).
Other vaccine strategies have assessed delivery of PfCelTOS
using viral vectored vaccines in inbred and outbred mice, however
these failed to protect against a challenge with chimeric P. berghei
parasites expressing the PfCelTOS antigen [16]. Another study
sought to combine multiple sporozoite targets, including the
PfCelTOS antigen, to broaden humoral and cellular responses.
Ferraro et al. evaluated a multi-subunit DNA-electroporation
delivery in mice and non-human primates (NHP) [17], and
reported plasmid-expressed PfCelTOS antigen-speciﬁc antibodies
and T cell responses. Recently a chimeric-molecule, composed
of three P. falciparum 3D7 pre-erythrocytic domains (PfCelTOS;
PfCSP-thrombospondin-related-type-1-repeat domain (-TSR);
and thrombospondin-related adhesion protein (PfTRAP)-TSR),
cine 3
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xpressed in Nicotiana benthamiana and delivered in Gerbu MM
djuvant induced antibodies in mice that recognized methanol-
xed sporozoites and inhibited invasion of hepatocytes up to
5%, although the speciﬁc contribution of PfCelTOS-antibodies
as not elucidated [18]. While early indications in preclinical
nimal studies are encouraging, the potential for efﬁcacy induced
y a PfCelTOS-based vaccine in humans is yet to be realized.
.2. PfAMA1
Apical membrane antigen 1 (AMA1) is a micronemal protein
hat is secreted onto the surface of both merozoites and sporo-
oites [19–21]. Historically PfAMA1 has been a leading malaria
accine candidate (see [22] for a detailed review) and antibodies to
MA1 in multiple Plasmodium species block merozoite invasion of
BC and sporozoite invasion of hepatocytes [21,23]. However, the
igh number of polymorphisms [24,25] and in vitro data showing
 predominantly allele-speciﬁc inhibition of anti-PfAMA1 antibod-
es [26,27] have dampened expectations. Approaches to vaccine
esign to try and overcome antigenic heterogeneity are reviewed
lsewhere in this series [Plowe et al.].
Despite promising data from NHP studies [28–30], a key ques-
ion is whether a PfAMA1-based vaccine can protect humans. This
as been evaluated by CHMI with homologous parasites in Phase
/IIa studies using protein- or viral vector-based vaccination strate-
ies [31–33]. Disappointingly, none of these studies, as well as two
ecent Phase IIb ﬁeld trials [34,35], showed any overall efﬁcacy
hen using vaccines based on PfAMA1 alone. It should be noted
hat another study using a DNA prime – adenoviral boost regime
eported 27% sterilizing efﬁcacy against mosquito-bite CHMI in
ealthy US adults when using vectored vaccines encoding PfAMA1
nd PfCSP [36]. Cellular immune responses against PfAMA1 were
argely associated with protective outcome [36,37]. Moreover, in
ne of the ﬁeld trials of a protein PfAMA1-based vaccine formu-
ated in AS02A adjuvant, 64% efﬁcacy against low frequency, 3D7
accine-type parasites, as deﬁned by homology at 9 out of over 60
olymorphic sites, was also observed [35]. This efﬁcacy was  not
bserved when the same population was followed over the next
alaria season despite sustained high antibody titers [38].
Lack of efﬁcacy with PfAMA1-based vaccines alone, at least
n the CHMI studies, cannot be attributed to polymorphisms
n PfAMA1 given that vaccine-homologous parasites were used
31–33]. Notably the PfAMA1 vaccines have been tested with adju-
ants such as AS01B and AS02A, which remain a leading delivery
echnology in humans for the induction of high antibody concen-
rations. Consequently, if insufﬁcient antibody titers are the reason
hat PfAMA1 vaccines failed to protect, then there remains a sig-
iﬁcant challenge to develop clinically relevant ways of improving
he magnitude of anti-PfAMA1-speciﬁc antibody [31,38]. However,
nother possible reason for the poor efﬁcacy in humans could
e due to the vaccines not inducing a threshold concentration of
unctional antibodies, despite the overall high anti-PfAMA1 titers.
ndeed, it remains unknown, for now, what proportion of vaccine-
nduced PfAMA1 antibodies in humans can provide functional
nti-parasitic activity. Recent efforts have largely aimed at enhanc-
ng strain-transcendent, neutralizing antibodies by incorporating
ultiple PfAMA1 alleles or mutagenesis to redirect the immune
esponse toward conserved regions [39–44], and one ‘diversity cov-
ring’ (DiCo) approach has just entered Phase Ia testing in Europe
Clinicaltrials.gov NCT02014727). These approaches increase the
epertoire of antibodies against multiple PfAMA1 alleles but do
ot, however, appear to enhance inhibition of homologous para-
ites. Therefore developing new approaches to boost the proportion
f functional antibodies, and improve the so-called “quality” of
he antibody response, against homologous parasites could help
dvance PfAMA1-based vaccines.3 (2015) 7433–7443 7435
Plasmodium merozoite invasion of RBC requires interaction of
AMA1 with a conserved 47 amino acid region of rhoptry neck
protein 2 (RON2, a parasite protein secreted onto the surface of
the RBC), leading to conformational changes in the AMA1 loop
regions surrounding the hydrophobic pocket [45–47]. Although the
importance of this interaction has been debated [48–50], antibod-
ies that bind the AMA1 loops block AMA1–RON2 interaction and
inhibit invasion [46,51,52]. Interestingly, many of the polymor-
phisms in PfAMA1 are present in loops surrounding the PfRON2
binding site [25], indicating immune selection and the importance
of these antibodies in protection. Since this form of AMA1 in com-
plex with RON2 is functional and possibly exposed on the surface
of the merozoite during invasion, a subunit vaccine mimicking this
structure could perhaps be better than AMA1 alone. Interestingly,
mice vaccinated with the Plasmodium yoelii AMA1–RON2L com-
plex, but not PyAMA1 alone, were protected against a virulent
P. yoelii challenge despite inducing similar levels of anti-PyAMA1
antibodies [53]. Consistent with this, IgG from animals immunized
with the complex also inhibited P. falciparum homologous para-
sites signiﬁcantly more than IgG from animals receiving PfAMA1
alone, suggesting a qualitative shift in the antibody response, i.e. a
higher proportion of vaccine-induced antibodies that are inhibitory
[53]. Indeed, preclinical evaluation in Aotus monkeys indicates
that vaccination with the complex provides signiﬁcantly higher
protection than PfAMA1 alone against a homologous FVO-strain
challenge (PS, LHM, unpublished). These data suggest that a thresh-
old level of functional, neutralizing antibodies could be induced by
a PfAMA1–RON2L complex vaccine to confer protection in humans.
Efforts are currently underway to assess whether this approach
provides protection in humans, and if combining a multi-allele
PfAMA1 vaccine in complex with RON2L can protect against both
homologous and heterologous parasites. It is tempting to speculate
that immune responses to such next-generation PfAMA1-based
vaccines may  be boosted through natural infections in malaria
endemic populations where PfAMA1 is one of the more immuno-
genic antigens.
2.3. PfMSP1
P. falciparum merozoite surface protein 1 (PfMSP1), the major
surface coat antigen on merozoites, has been extensively inves-
tigated as a blood-stage vaccine candidate, primarily based on
reports that anti-PfMSP1 antibodies are associated with decreased
risk of clinical malaria, albeit, in an allele-speciﬁc manner [54].
To date, numerous PfMSP1-based vaccine trials have been com-
pleted, with all candidates being considered safe and immunogenic
[55]. However, no vaccine candidate comprising of any portion of
PfMSP1 has shown either efﬁcacy or reduction of parasite multi-
plication rates (PMR) following homologous CHMI [33,56,57], or
following natural infection in Phase IIb ﬁeld trials [58,59]. It should
be noted that, unlike for the PfAMA1 protein vaccine discussed
above, sieve analysis of the PfMSP1 ﬁeld trial data has not been
reported and could provide valuable insight. Such analyses are
important in order to document the potential value of a vaccine
candidate antigen, whereby a positive outcome then shifts the chal-
lenge to approaches for overcoming antigenic diversity.
Early strategies for PfMSP1 focused on antibody induction
using subunit protein-in-adjuvant vaccines [59,60] in heterologous
allelic combinations [61] and multi-subunit combinations [62].
More recent clinical strategies have incorporated viral vectored
prime-boost regimens to broaden immunity toward functional
CD4+/CD8+ T cell induction [63], and in multi-subunit combina-
tions [33]. In the latter cases, induction of effector T cells was unable
to overcome limitations in the induction of effective antibody lev-
els. To further assess PfMSP1-antibody functionality, in vitro assays
of parasite growth/invasion inhibition activity (GIA/IIA) were
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erformed on immune sera or puriﬁed immunoglobulins. In gen-
ral, modest to low levels of GIA were detected from vaccinated
alaria-naïve subjects.
While PfMSP1 vaccine development has largely yielded disap-
ointing outcomes in clinical investigations, several new efforts
re focused on alternate expression hosts to improve subunit
tructure [64,65]; on forming chimeric molecules to broaden allele-
nd target-speciﬁc immunity [66–69]; on PfMSP1-nanoparticle
elivery platforms [70,71]; on aggregates and chemical-conjugates
72]; and on viral vectored vaccines in prime-boost regimens co-
xpressing molecular adjuvants [73]. Despite signiﬁcant hurdles to
heir development and evaluation, some limited improvements in
fMSP1-speciﬁc antibody functionalities have been reported from
nimal studies. While these ﬁndings may  be promising, it remains
o be seen whether they are sufﬁcient to exceed the limitations in
ntibody magnitude, speciﬁcity and functionality observed to-date
n humans.
.4. PfRH5
In recent years P. falciparum reticulocyte-binding protein
omolog 5 (PfRH5) has emerged as a promising vaccine candi-
ate antigen against the blood-stage merozoite [74] which, similar
o PfMSP1 and PfAMA1, has been assessed using the standard-
zed cell-independent in vitro assay of GIA. Antibodies induced by
fRH5 vaccination in preclinical in vitro studies have been shown
o overcome two long-standing difﬁculties associated with other
erozoite antigens: ﬁrst, they can block erythrocyte invasion to
igh efﬁciency (with lower EC50 in terms of antigen-speciﬁc anti-
ody concentration than other known antigens [75]); and second,
ntibodies induced by monovalent vaccines cross-inhibit all P. fal-
iparum lines and ﬁeld isolates tested to-date [74–77]. Notably
hese antibodies have been raised by using full-length PfRH5
mmunogens, in contrast to earlier work that failed to induce
unctional antibodies when using fragments of the antigen made
n E. coli [78,79]. Generation of full-length PfRH5 protein proved
articularly problematic, and thus the earliest promising results
ere achieved using viral vectored immunization [74], whereby
ntigen is expressed in situ from virally infected muscle cells
80]; also see Ewer et al. in this review series. Since that time,
ubstantial progress has been made with reports of successful
ull-length PfRH5 protein production from numerous heterologous
xpression systems including mammalian HEK293 cells [81], E. coli
77,82], baculovirus-infected insect cells [83,84], wheatgerm [85],
nd Drosophila S2 stable cell lines [86], but notably not yeast-based
ystems.
Production of PfRH5 antigen in mammalian cells led to the iden-
iﬁcation of its RBC surface receptor, basigin, with which it forms a
ritical non-redundant interaction during invasion [87]. The PfRH5
ene is also refractory to genetic deletion [78,88], conﬁrming the
ssential nature of its function, however, in the context of natu-
al infection, PfRH5 does not appear to be a dominant target of
aturally acquired immune responses [74,89–91]. The high degree
f PfRH5 sequence conservation is thus associated with low-level
atural immune pressure, but also functional constraints linked
o basigin binding. Minimal amino acid substitutions in PfRH5
ccount for loss of basigin binding and/or host RBC tropism (linked
o binding basigin orthologues from other species), suggesting the
ntigen may  not easily escape vaccine-induced immune pressure
88,92,93].
Most recently high-level efﬁcacy was reported for the ﬁrst
ime against a stringent heterologous strain blood-stage chal-
enge in an in vivo Aotus monkey-P. falciparum challenge model,
ollowing vaccination with viral vectors or PfRH5 protein pro-
uced from mammalian HEK293 cells [94]. Protection was  strongly
orrelated with anti-PfRH5 serum IgG antibody concentration3 (2015) 7433–7443
and in vitro functional GIA [94], conﬁrming the utility of this
assay to predict in vivo protection and for future vaccine can-
didate down-selection. There is now signiﬁcant momentum to
progress PfRH5-based vaccines into clinical trials. Although the
ﬁrst candidate to enter the clinic is utilizing viral vectored delivery
(Clinicaltrials.gov NCT02181088), at least one full-length protein
immunogen has entered cGMP production in Oxford, UK using the
Drosophila S2 cell expression platform [95]. With recent reports of
the crystal structure of PfRH5 bound to basigin and neutralizing
mouse monoclonal antibodies (mAbs) [84,86,96], future devel-
opments will likely see rationally designed second-generation
protein immunogens seeking to focus antibody induction on crit-
ical areas of the molecule. It is likely PfRH5 immunogens will also
be developed using various VLP technologies to maximize antibody
induction, and the ﬁrst VLP of bacteriophage MS2  isolated against
an inhibitory mAb  has already been reported [97]. VLP platforms
are also reviewed elsewhere in this series [Wu  et al.]. Further-
more, the recent elucidation of a protein complex containing PfRH5
and two binding partners – PfRH5-interacting protein (PfRipr) and
the GPI-anchored cysteine-rich protective antigen/PfRH5-PfRipr
membrane-anchoring protein (PfCyRPA/PfRRMAP) [98,99], sug-
gests further opportunities to improve vaccine potency – both
antigens elicit functional antibodies alone [82,98–100], and IgG
responses induced in rats by PfRH5 and PfCyRPA proteins produced
in E. coli have been shown to synergize [75,99].
2.5. PfSERA5
One family of proteases associated with the merozoite surface
and known to be involved in the egress of P. falciparum merozoites
from blood-stage schizonts is the large multigene family of ser-
ine repeat antigens (SERAs) [101,102]. Of nine members, PfSERA5
is strongly expressed in schizont stages (approximately 0.5–1.5%
of the total mRNA) [103] and, together with PfSERA6, is refractory
to deletion and essential for parasite growth [104–106]. PfSERA5-
based vaccine candidates were shown to induce antibodies that
either protected against blood stage infection in vivo [107] or
inhibited parasite growth in vitro [108,109]. Recombinant proteins
made from the N-terminal domains of PfSERA5 have been shown
to be immunogenic and elicited antibodies that inhibited erythro-
cyte invasion and parasite replication in vitro and in animal models;
as well as inversely correlate with parasite density and/or malaria
symptoms in sero-epidemiological studies in Uganda and Solomon
Islands (reviewed in [110]). It is still a challenge to elucidate
the exact role(s) of PfSERA5 but selective inhibitors of subtilisin-
like serine protease subtilase 1 (PfSUB1), an enzyme involved in
the processing of PfSERA5, have been shown to inhibit merozoite
egress and parasite maturation [111–115]. The signiﬁcance of the
tight temporal, yet extensive processing steps of PfSERA5 remain
to be fully understood. In some studies, other than proteolysis
[116], some regulatory roles (chaperone-like function or substrate
recognition and binding) have also been suggested [114,117]. An
immunological “smoke screen” or blocking of the complement
pathway is also possible [118,119].
The SE36 vaccine candidate is a recombinant form of the
PfSERA5 N-terminal domain without the polyserine repeats.
Expressed in E. coli, there are two  products under clinical tri-
als: BK-SE36 with aluminum hydroxide gel [120] and a recent
iteration, comprising of BK-SE36 and the TLR9 agonist CpG (BK-
SE36/CpG) [121]. The BK-SE36 malaria vaccine showed a favorable
safety proﬁle in Japanese male adults and in a malaria-exposed
population in Uganda aged 6–>20 years old. Local adverse reac-
tions were comparable to other alum-based vaccines: induration,
tenderness, pain, swelling, erythema and redness were reported
[120]. Immunogenicity analyses indicate that high seroconversion
was achieved by vaccination of 1 mL  BK-SE36 (equivalent to 100 g
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E36 protein and 1 mg  aluminum hydroxide gel) in malaria-naïve
ealthy Japanese adults and in individuals with low pre-existing
nti-SE36 antibody in the malaria-exposed population [120]. Low
eroconversion in malaria exposed adults might be interpreted as
mmunotolerance in this age group, as observed in other clinical tri-
ls [122,123]. Nevertheless, immunogenicity was remarkably high
n the 6–10 year old age group in Uganda. In an ancillary analysis
rom follow-up of the Phase Ib study, vaccination with BK-SE36
as shown to confer over 70% protection against symptomatic
alaria for one year [120]. Antibody titer changes and dynamics
f malaria infection also suggest that antibody titers against SE36
ere boosted after episodes of natural infection, at least for indi-
iduals where doubling of antibody titers from the pre-vaccination
iter was observed Yagi, Horii et al. (unpublished). Additionally,
nalysis of sera5 allele haplotype diversities and haplotype frequen-
ies were similar between parasite isolates from infected vaccinees
nd the control group (Arisue et al., unpublished data). Impor-
antly, unlike other blood-stage vaccine candidates, the N-terminal
egions possessing inhibitory epitopes are intrinsically unstruc-
ured [119], thus strict tertiary structure may  not be required to
licit protective antibodies. Further studies using the CpG adjuvant
o improve the immunogenicity of the antigen is in Phase Ia clinical
rial (Horii et al., unpublished), and formal Phase II efﬁcacy testing
f the SE36 candidate will be eagerly awaited.
.6. PfGLURP, PfMSP3 and Pfs48/45
Further efforts in the ﬁeld have focused on the P. falciparum
erozoite antigens glutamate-rich protein (PfGLURP) and PfMSP3,
ore recently combined with the gametocyte antigen Pfs48/45.
election of these target antigens and subunit vaccine design was
uided by observations made from studies of naturally acquired
mmunity (NAI), in vitro functional bioassays and assessment in
reclinical/clinical studies. Expression of two recombinant subunit
accine candidates to-date has relied on the use of Lactococcus lactis
a generally recognized as safe or ‘GRAS’ organism). These include
MZ2 (a fusion of PfGLURP and PfMSP3) targeting the asexual
lood-stage and aimed at reducing the parasite load in order to con-
er protection against clinical malaria, and more recently Pfs48/45,
imed at targeting the parasite’s sexual development within the
osquito and thus seeking to reduce parasite transmission.
GMZ2 is a hybrid protein [124] consisting of conserved domains
f the two asexual blood stage antigens from P. falciparum –
LURP27–500 and MSP3212–380 [125,126], aimed to mimic  pathogen
omponents that induce premunition, a state of NAI against P. fal-
iparum malaria [127]. The PfGLURP and PfMSP3 components of
MZ2 were chosen to be combined as a hybrid protein based on
 series of immuno-epidemiological studies from geographically
iverse epidemiological settings [128–133] with some syner-
ism observed between naturally occurring antibodies against
oth antigens [132]; functional in vitro studies [133,134]; and
opulation genetic studies of malaria exposed children [135].
otably the selection of these candidate antigens was prioritized
n the basis of the ability of antigen-speciﬁc antibodies to elicit
ntibody-dependent cellular inhibition (ADCI) in conjunction with
onocytes, as opposed to cell-independent neutralization in the
ssay of GIA as used to assess vaccines based on PfMSP1, PfAMA1
nd PfRH5. Clinical development of GMZ2 has focused on the use of
n Alhydrogel (alum) adsorbed formulation which has proven to be
afe and well tolerated in preclinical toxicology studies [136]. This
MZ2/alum formulation has been tested in three Phase Ia/b stud-
es in (i) malaria-naïve German adults [137]; (ii) partially immune
abonese adults [138]; and (iii) Gabonese children aged 1–5 years
139]. All these trials have shown GMZ2/alum to be safe, well tol-
rated and immunogenic. Recently, it was demonstrated that the
MZ2/alum formulation elicits antibody titers in humans which3 (2015) 7433–7443 7437
are equivalent to those obtained after years of natural exposure
[140]. It was therefore decided to test the GMZ2/alum formulation
in a multicenter Phase IIb trial in African children to assess safety,
tolerability and efﬁcacy in the target population. Results from this
trial are awaited.
The Pfs48/45 protein is expressed during the sexual differ-
entiation of the parasite into gametocytes [141] and consists
of cysteine-rich domains with multiple disulﬁde bonds. These
constitute distinct conformational B cell epitopes recognized by
several mAbs with transmission-blocking activity (TBA) [142]. Dur-
ing their development in the human host, gametocytes remain
intra-erythrocytic and are relatively sheltered from the effects of
the immune system. However, once inside the mosquito midgut
the parasite develops into extra-erythrocytic gametes, exposing
Pfs48/45 on their surface, where the antigen can be targeted by
antibodies and other components of the blood meal [141]. Naturally
acquired anti-Pfs48/45 antibodies are present in endemic popu-
lations, and the occurrence of these antibodies is associated with
TBA when tested in the standard membrane feeding assay (SMFA)
[143–146]. Overcoming the challenges related to the recreation
of the native conformation of Pfs48/45 [147–154], recently led to
the production of the carboxy-terminal 10C-fragment of Pfs48/45
(containing three known epitopes for transmission-blocking anti-
bodies) as a chimera with the N-terminal R0 region of PfGLURP
[155]. This resulting chimeric protein elicited broadly inhibiting
antibodies against both asexual- and transmission-stages of P. fal-
ciparum. Further variants with a truncated 10C region are now
being explored and show promise in terms of improved yield and
induction of functional antibodies in rats [156]. A combination vac-
cine with antigens from both asexual- and transmission-stages may
provide both direct protection against clinical disease and indirect
beneﬁt by reducing the spread of the parasite in the population.
The future assessment of the merits of such multi-stage subunit
approaches in humans will be a key focus of research.
2.7. Pfs25
Pfs25, a 25-kDa surface antigen of zygotes and ookinetes is cur-
rently the most developed transmission-blocking vaccine (TBV)
candidate in the pipeline and the only one that has been tested
in human clinical trials [157], along with its ortholog Pvs25 from P.
vivax [158]. Anti-Pfs25 antibodies induced in humans after vaccina-
tion with soluble Pfs25 protein in Montanide ISA51 are functional
in the ex vivo SMFA and signiﬁcantly block the development of both
laboratory strain and ﬁeld isolates (from gametocyte donors) of P.
falciparum [158].
To-date Pfs25 has been successfully produced in a variety of
expression systems as a soluble protein unlike the cysteine rich
pre-fertilization targets (Pfs48/45 and Pfs230 region C) which have
proven more difﬁcult to express in heterologous systems [157]. The
TBA of antibodies against Pfs25 usually correlates with the antibody
titer, and in humans the absolute concentration of anti-Pfs25 spe-
ciﬁc IgG required to achieve signiﬁcant blocking is high (86 g/mL
IC50 in the SMFA) [159]. In order to achieve high antibody titers
in humans, vaccine candidates will therefore likely require strong
chemical adjuvants and/or highly immunogenic delivery platforms.
The most potent chemical adjuvants can lead to unacceptable lev-
els of reactogenicity, as reported in the Phase Ia clinical trial of a
soluble Pfs25-Montanide ISA51 formulation [158]. Future trials of
vaccine candidates with other leading adjuvants in clinical devel-
opment, such as AS01B or GLA-SE, will hopefully show acceptable
reactogenicity proﬁles.There has been substantial recent interest in developing
improved delivery platforms for Pfs25 protein either by conjugat-
ing Pfs25 to carrier proteins or displaying Pfs25 on VLPs. Soluble
Pfs25 has been produced in E. coli after codon harmonization [160],
7 cine 33 (2015) 7433–7443
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Box 1: Anticipated future developments for protein-
based malaria vaccines.
• Antigen Discovery: New and promising vaccine candidate
antigens from the sporozoite-, merozoite- and sexual-stage
parasites will be discovered from numerous approaches
making use of “-omic” datasets [5] [Doolan et al. in this
review series]. Antigens that are conserved, essential, not
necessarily dominant targets of naturally acquired immunity
and yet antibody-susceptible would be attractive targets for
protein-based vaccines.
• Antigen Combinations: These will be explored empirically
and rationally, seeking to deﬁne combinations of antigens
against the same or multiple lifecycle stages that can provide
additive, or ideally synergistic, beneﬁt in terms of protective
efﬁcacy [75,181].
• Structure-based Immunogen Design: Development of
new protein-based immunogens will beneﬁt from structural
understanding of how human antibodies successfully block
their parasitic targets. Focus may shift from antigen targets
per se to ‘epitope-based’ targets, with structural biology
guiding the design of improved peptide-based vaccines [182]
[Patarroyo ME et al. companion paper]; or protein-based vac-
cines, as being currently explored for viral pathogens such
as HIV, inﬂuenza and RSV [183,184].
• New Protein Expression Platforms for cGMP Produc-
tion: It is likely that new heterologous expression systems
will be developed to produce new-generation immuno-
gens for malaria, complementing existing capabilities in
bacterial- and yeast-based systems. Insect cell platforms
have already been progressed for PfRH5 and VAR2CSA [95],
and mammalian cell-based platforms have proved excep-
tionally valuable in preclinical studies for the expression of
full-length malaria proteins [81].
• Improved Protein Vaccine Delivery Platforms: New
generation protein-based vaccines will explore a range
of novel delivery platforms seeking to improve antibody
immunogenicity in humans. A range of VLP-, particle- or
vesicle-based technologies will likely be tested for their abil-
ity to deliver arrayed antigen as a highly immunogenic
composition. Mixed-modality prime-boost immunization
regimes incorporating vectored- and protein-based com-
ponents will seek to maximize both cellular and humoral
immune responses [80,185,186]. Improved understanding of
B cell and CD4+ T follicular helper cell responses [187,188]
could guide the development of vaccine delivery platforms
that can enhance the peak and/or longevity of the antibody
response.
• Adjuvants: On-going development of new vaccine adju-
vants, designed on the basis of improved understanding of
innate immune sensing mechanisms, will likely be tested
with protein-based malaria vaccines seeking high-titer anti-
body induction.
• Assay Development and Quantitative Vaccine Assess-
ment: The on-going development of in vitro/ex vivo assays
and assessment of their relationship to in vivo malaria pro-
tection will remain an important focus of research. The ability
to quantitatively measure antigen-speciﬁc antibody concen-
trations and their related functional activity should allow for
the prioritization of new antigens that are inherently more
susceptible to antibodies [75,94,159,189], or the deﬁnition of
immunogens that elicit qualitatively improved IgG responses
[53].
• CHMI Models: The continued use of CHMI models in Phase438 S.J. Draper et al. / Vac
he wheatgerm cell-free system [161], mammalian HEK293 cells
ikolaeva, Biswas et al. (unpublished), plant-based N. benthamiana
162] and Chlamydomonas reinhardtii [163], and in yeast (P. pastoris
nd S. cerevisiae)  [164,165]. To-date, protein produced in yeast is
he best characterized and the one tested in human clinical trials
158].
Pfs25 has been conjugated to itself [166], NANP repeats of the
fCSP [167], or to carrier proteins like covalent conjugation to outer
embrane protein complex (OMPC) of Neisseria meningitides [168],
xoprotein A of Pseudomonas aeruginosa (EPA) [169] and cholera
oxin subunit B [170]. Studies in Oxford have recently fused Pfs25
o IMX313, a protein heptamerization technology [73,171], leading
o the expression of a nanoparticle in P. pastoris and signiﬁcantly
mproved antibody titers and TBA in preclinical studies Lee, Biswas
t al. (unpublished). Indeed, most of these efforts have led to sig-
iﬁcant increase in anti-Pfs25 antibody titer and TBA. In the study
here Pfs25 was  conjugated to OMPC, the results were highly
ncouraging as the antibody response in macaques persisted at
igh-levels for over 18 months [168] – a highly desirable attribute
or any vaccine seeking to block malaria transmission for prolonged
eriods of time. The Pfs25-EPA conjugate formulated with Alhydro-
el has now been tested in malaria-naïve adult volunteers in the
SA, with extension to Phase Ib ﬁeld trials in Mali underway. Most
ecently, a clinical study has begun in the USA to assess a combi-
ation of this vaccine with another consisting of EPA conjugated
o a region of the gametocyte antigen Pfs230 (Clinicaltrials.gov
CT02334462). The Fraunhofer Institute has also developed a VLP
y fusion of Pfs25 to the Alfalfa mosaic virus coat protein, expressed
n N. benthamiana, which is also currently being tested in humans.
he results of these most recent clinical trials of Pfs25-based con-
ugates are eagerly awaited.
. Concluding remarks
The development of a highly effective vaccine against Plas-
odium parasites has proved exceptionally challenging, but
rotein/adjuvant subunits have to-date provided at least one par-
ially efﬁcacious product based on the PfCSP antigen in the form
f RTS,S/AS01B [8]. Protein vaccine candidates against other tar-
ets have proved disappointing in Phase IIa/b efﬁcacy trials, but
he continued need to innovate has driven much progress in terms
f antigen design, expression, cGMP production and human deliv-
ry. Efﬁcacy results from on-going trials of GMZ2 and SE36 remain
agerly awaited; improved formulations and iterations of PfMSP1,
fAMA1, Pfs25 and PfCelTOS are under active development or
n clinical trials; and new antigens such as PfRH5, Pfs230 and
fs48/45 amongst others are entering cGMP production or Phase
a clinical testing. Nevertheless, it is likely that a highly effec-
ive vaccine seeking to prevent death, disease or transmission,
s required by the recently updated Malaria Vaccine Technology
oadmap to 2030 [172], will necessitate new strategies; and key
evelopments likely to be seen in the near future are outlined
n Box 1 . The next few years promise to be an exciting time as
hese new candidates, formulations and approaches are assessed in
umans.
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IIa clinical trials will allow for rapid efﬁcacy assessment
of new protein vaccine candidates and formulations. Vac-
cines targeting the pre-erythrocytic stages can now be tested
using the mosquito-bite or cryopreserved sporozoite (PfSPZ
Challenge) models [190,191]. While the possible effect(s) of
blood-stage vaccines on high-level parasitemia cannot be
S.J. Draper et al. / Vaccine 3
explored in the context of CHMI for obvious safety rea-
sons [192], on-going efforts are aiming to reﬁne the use
of the blood-stage CHMI model [193] to assess the impact
of new blood-stage vaccines on the parasite multiplication
rate (PMR) [194] prior to diagnosis by thick-ﬁlm microscopy
Payne, Draper et al. (unpublished). Other novel approaches
using CHMI models, including sub-curative drug treatment
regimes, should allow for gametocyte induction and test-
ing of P. falciparum transmission-blocking vaccines. The
development of cryopreserved sporozoites and blood-stage
inocula is now enabling the ﬁrst modern CHMI studies in
malaria-endemic countries [195] and will allow for proof-of-
concept vaccine testing in the target population, including
individuals with existing degrees of natural immunity. The
development of new P. falciparum parasite strains for CHMI
[196,197], beyond the historical NF54 strain/3D7 clone, will
enable more informative assessment of vaccines against
heterologous parasites and more recent isolates; while the
establishment of blood-stage inocula for P. vivax will allow
expansion of efforts into vaccine testing against a second
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